tbuckley/cabot-search huggingface dataset:
Dopamine Antagonists in ICU Delirium
Authors: Thomas P. Bleck
Journal: New England Journal of Medicine (2018)

Perhaps the most vexing problem in a patient in an intensive care unit (ICU) is an unexpected change in mental status. Historically, "acute encephalopathy" was the term used to encompass such alterations, but "delirium" is now used to describe this state. The Oxford English Dictionary defines delirium as "an acutely disturbed state of mind characterized by restlessness, illusions, and incoherence that are occurring in intoxication, fever, and other disorders"; this was the concept based on the prototype of delirium tremens. With the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-4), the definition of delirium was expanded to "disturbance . . .
GW29-e1069 The impact of continuous positive airway pressure on heart rate variability in obstructive sleep apnea patients during sleep: a meta-analysis
Authors: Wenjia Guo, None Lvtingting, Rong He, Fei She, Nang Kham Nu, Jing Yang, Kun Li, Ping Zhang
Journal: Journal of the American College of Cardiology (2018)
Signal transduction pathway activity during neoadjuvant treatment in esophageal adenocarcinomas
Authors: A. Creemers, S.L. Meijer, M. Stoffels, G.K.J. Hooijer, L. Holtzer, H. van Ooijen, A. Van Brussel, E.M.G. Aussems-Custers, M. van Berge Henegouwen, M.C.C.M. Hulshof, K.K. Krishnadath, A. van de Stolpe, M.F. Bijlsma, H.W.M. van Laarhoven
Journal: Annals of Oncology (2018)
A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients
Authors: L. Häberle, R. Erber, P. Gaß, A. Hein, S.M. Jud, H. Langemann, C. Rauh, C.C. Hack, R. Schulz-Wendtland, A. Hartmann, M.W. Beckmann, M.P. Lux, P.A. Fasching
Journal: Annals of Oncology (2018)
Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial
Authors: V.G. Atkinson, A. Hauschild, M. Santinami, M. Mandala, V. Chiarion Sileni, J. Larkin, M.S. Nyakas, C. Dutriaux, A. Haydon, L. Mortier, C. Robert, J. Schachter, D. Schadendorf, X. Feng, E. de Jong, B. Mookerjee, R. Kefford, R. Dummer, J.M. Kirkwood, G.V. Long
Journal: Annals of Oncology (2018)
Doubly Randomized Preference Trial of Prolonged Exposure Versus Sertraline for Treatment of PTSD
Authors: Lori A. Zoellner, Peter P. Roy-Byrne, Matig Mavissakalian, Norah C. Feeny
Journal: American Journal of Psychiatry (2018)

The authors examined the effect of patient treatment preference on the differential effectiveness of prolonged exposure and sertraline for the treatment of posttraumatic stress disorder (PTSD).In a doubly randomized preference trial, 200 patients with PTSD viewed standardized treatment rationales prior to randomization. Patients were first randomized to choice of treatment or no choice. Those assigned to no choice were then randomized to prolonged exposure or sertraline. Acute treatment was 10 weeks, with 24-month follow-up. Interviewer-rated PTSD symptom severity was the main outcome measure, and depression, anxiety, and functioning were assessed as additional outcomes.Patients preferred prolonged exposure over sertraline (number needed to benefit [NNTB]=4.5). Using intent-to-treat analyses (N=200), both prolonged exposure and sertraline showed large gains that were maintained over 24 months. Although no differential effect was observed on interviewer-rated PTSD severity, there was a significant benefit of prolonged exposure over sertraline on interview-rated loss of PTSD diagnosis (NNTB=7.0), responder status (NNTB=5.7), and self-reported PTSD, depression, and anxiety symptoms and functioning (effect sizes, 0.35-0.44). Patients who received their preferred treatment were more likely to be adherent, lose their PTSD diagnosis (NNTB=3.4), achieve responder status (NNTB=3.4), and have lower self-reported PTSD, depression, and anxiety symptoms (effect sizes, 0.40-0.72).Prolonged exposure and sertraline confer significant benefits for PTSD, with some evidence of an advantage for prolonged exposure. Giving patients with PTSD their preferred treatment also confers important benefits, including enhancing adherence.
Abstract 12977: Plasma Estradiol Levels, Estrogen Receptor Polymorphisms and Ischemic Arterial Disease in Postmenopausal Women: The Three-city Prospective Cohort Study
Authors: Valérie Scarabin-Carré, Sylvie Brailly-Tabard, Maurice Giroud, Joanne Ryan, Catherine Helmer, Anne Guiochon-Mantel, Marianne Canonico, Pierre-Yves Scarabin
Journal: Circulation (2013)

Background: High levels of endogenous estrogen have been related to adverse health outcomes, including ischemic arterial disease (IAD), in older postmenopausal women. Whether estrogen receptor poly...
GW29-e0102 The Relationship between Estimated Glomerular Filtration Rate and Contrast-induced Acute Kidney Injury in Patients who underwent an Emergency Percutaneous Coronary Intervention
Authors: Ying Yuan, Xiaoying Hu, Tong Luo, Xiaojin Gao, Xueyan Zhao, Jun Zhang, Yuan Wu, Shubin Qiao, Yuejin Yang, Runlin Gao, Hong Qiu
Journal: Journal of the American College of Cardiology (2018)
Factors Associated With Cancer Disparities Among Low-, Medium-, and High-Income US Counties
Authors: Jeremy M. O’Connor, Tannaz Sedghi, Meera Dhodapkar, Michael J. Kane, Cary P. Gross
Journal: JAMA Network Open (2018)

<h3>Background</h3> There are concerns about the degree to which county income level might underlie the stark disparities in cancer death rates among US counties; at the same time, there is uncertainty about the factors that may mediate the disparities. <h3>Objectives</h3> To assess county-level cancer death rates and to identify possible mediators of the association between county-level median incomes and cancer death rates. <h3>Design, Setting, and Participants</h3> Cross-sectional study using death records from the National Center for Health Statistics in 2014, with data collected and analyzed between October 1, 2016, and July 31, 2017. All US counties and county equivalents were included. <h3>Exposures</h3> County-level median household income. <h3>Main Outcomes and Measures</h3> County-level age-standardized cancer death rate. <h3>Results</h3> In 3135 counties, median incomes ranged from $22 126 to $121 250 per year. Low-income counties (median income, $33 445) vs high-income counties (median income, $55 780) had higher proportions of residents who were non-Hispanic black, lived in rural areas, or reported poor or fair health. The mean (SD) cancer death rate was 185.9 (24.4) per 100 000 person-years in high-income counties, compared with 204.9 (26.3) and 229.7 (32.9) per 100 000 person-years in medium- and low-income counties, respectively. In mediation models, health risk behaviors (smoking, obesity, and physical inactivity); clinical care factors (unaffordable care and low-quality care); health environments (food insecurity); and health policies (state smoke-free laws and Medicaid payment rates) in aggregate accounted for more than 80% of the income-related disparity. The strongest possible mediators were food insecurity (explaining 19.1% [95% CI, 12.5%-26.5%] of the association between county incomes and cancer deaths), low-quality care (17.9%; 95% CI, 14.0%-21.8%), smoking (12.7%; 95% CI, 9.4%-15.6%), and physical inactivity (12.2%; 95% CI, 9.4%-15.6%). <h3>Conclusions and Relevance</h3> There are wide gaps in cancer death rates between low-, medium-, and high-income counties. Future studies are needed to assess whether targeting the possible mediators might ameliorate the substantial socioeconomic cancer disparities.
New cancer supportive care system based on the outpatient chemotherapy unit in immune-checkpoint inhibitor era
Authors: Hidenori Takahashi, Yuji Satomi, Takeshi Suzuki, Aiko Kamiyama, Takeo Ishii, Airtimo Nanba, Natsumi Iguchi, Tetuso Hirata, Katsuya Takemura, Nobuhisa Nakajima, Masato Masuda, Akira Arasaki
Journal: Annals of Oncology (2018)
PAMAM dendrimers: blood-brain barrier transport and neuronal uptake after focal brain ischemia
Authors: Sofia D. Santos, Miguel Xavier, Diana M. Leite, Débora A. Moreira, Beatriz Custódio, Marília Torrado, Rita Castro, Victoria Leiro, João Rodrigues, Helena Tomás, Ana P. Pêgo
Journal: Journal of Controlled Release (2018)
GW29-e0632 Pathogenic mechanism and gene correction for LQTS-causing double-mutations in KCNQ1 using pluripotent stem cell model
Authors: Zhen Wang, Yangming Wang, Shiqiang Wang, Wenling Liu, Dayi Hu, Yuanfeng Gao, Qing Ge, Lei Li, Cuilan Li
Journal: Journal of the American College of Cardiology (2018)
GW29-e1493 Delays from symptoms onset to on the thrombolytic therapy in patients with ST-segment Elevation Myocardial Infarction among non-PCI hospitals in China: results from the CPACS-3 study
Authors: Lin Feng, Wuxiang Xie, Aihua Zhang, Licheng Lei, Xian Li, Runlin Gao, Yangfeng Wu
Journal: Journal of the American College of Cardiology (2018)
The National Cancer Institute (NCI) consortium of cohorts
Authors: Chinonye Harvey, Shannon Lynch, Scott Rogers, Deborah Winn
Journal: Cancer Research (2008)

3865   An Epidemiologic consortium is a group of scientists from multiple institutions who have agreed to cooperative research efforts involving, but not limited to, pooling of information from multiple population studies for the purpose of combined analyses. It is able to address scientific questions that cannot otherwise be addressed through the effort of investigators at a single institution. The National Cancer Institute (NCI) sees consortia as providing unique opportunities for advancing cancer epidemiology by virtue of the large sample size of study participants and the synergy resulting from the interdisciplinary expertise of the membership. First convened in 2000, the Cohort Consortium (CoCo) is one of the largest research consortia supported by the NCI; comprised of 34 U.S. and international cohorts, totaling 3.5 million study participants. The purpose of CoCo is to serve as a research resource providing data and biospecimens to study gene-gene and gene-environment interactions in the etiology of cancer. Four major initiatives, each of them comprised of a group of CoCo studies and investigators, have emerged from the CoCo and more are encouraged. These initiatives will be described here.      The four major initiatives are: 1) The Breast and Prostate Cancer Cohort Consortium (BPC3) which pools data and biospecimens from 10 prospective cohorts to conduct research on gene-environment interactions in breast and prostate cancer etiology. Data are drawn from about 8,000 prostate cancer patients and about 6,000 breast cancer patients. 2) Pancreatic Cancer Cohort Consortium (PanScan) is conducting a genome-wide scan of pancreatic cancer cases and controls from 12 cohorts, to identify markers of susceptibility to pancreatic cancer in 1,200 incident pancreatic cancer cases and 1,200 controls. 3) Rare Cancers Vitamin D Pooling Project (VDPP), the newest initiative, is a nested case-control study involving 10 cohorts to conduct pooled analyses of the associations between serum 25-hydroxy vitamin D concentrations and the development of rarer cancers (pancreatic, ovarian, lymphoma, upper gastrointestinal, endometrial and renal). Approximately 10,000 cases and matched controls will be assayed and analyzed.  We will use selected findings from some of these initiatives to illustrate the power of this approach. The findings from these studies would not have been possible without the formation of a large scale research collaboration. Collaboration in the consortium enables investigators to share data and resources, expand study populations, benefit from each others experiences, and create opportunities to pursue unique research studies.
Targeting metabolic flexibility via angiopoietin-like 4 protein sensitizes metastatic cancer cells to chemotherapy drugs
Authors: Maegan Miang Kee Lim, Jonathan Wei Kiat Wee, Jen Chi Soong, Damien Chua, Wei Ren Tan, Marco Lizwan, Yinliang Li, Ziqiang Teo, Wilson Wen Bin Goh, Pengcheng Zhu, Nguan Soon Tan
Journal: Molecular Cancer (2018)

Overcoming multidrug resistance has always been a major challenge in cancer treatment. Recent evidence suggested epithelial-mesenchymal transition plays a role in MDR, but the mechanism behind this link remains unclear. We found that the expression of multiple ABC transporters was elevated in concordance with an increased drug efflux in cancer cells during EMT. The metastasis-related angiopoietin-like 4 (ANGPTL4) elevates cellular ATP to transcriptionally upregulate ABC transporters expression via the Myc and NF-κB signaling pathways. ANGPTL4 deficiency reduced IC50 of anti-tumor drugs and enhanced apoptosis of cancer cells. In vivo suppression of ANGPTL4 led to higher accumulation of cisplatin-DNA adducts in primary and metastasized tumors, and a reduced metastatic tumor load. ANGPTL4 empowered cancer cells metabolic flexibility during EMT, securing ample cellular energy that fuels multiple ABC transporters to confer EMT-mediated chemoresistance. It suggests that metabolic strategies aimed at suppressing ABC transporters along with energy deprivation of EMT cancer cells may overcome drug resistance.
T-bet in Tfh cells: Now you see me, now you don’t
Authors: Susan M. Kaech
Journal: The Journal of Experimental Medicine (2018)

In this issue, Fang et al. (https://doi.org/10.1084/jem.20180927) report on a subset of T follicular helper (Tfh) cells that transiently expresses T-bet yet continues to produce IFN-γ at late stages of GC reactions following immunization. They find other genes uniquely expressed in this IFN-γ–producing Tfh subset, such as NKG2D, that can be used to better distinguish these functionally distinct Tfh cells.
Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study
Authors: E. Pohl, A. Schneeweiss, J. Hauke, V. Moebus, J. Furlanetto, C. Denkert, P.A. Fasching, C. Hanusch, H. Tesch, N. Weber-Lassalle, V. Müller, K. Rhiem, M. Untch, K. Luebbe, B. Lederer, C. Jackisch, V. Nekljudova, R.K. Schmutzler, E. Hahnen, S. Loibl
Journal: Annals of Oncology (2018)
P3.11-15 Lung Cancer Symptom Perception and Intervention Preferences in the UK’s Most Deprived Communities: A Qualitative Study
Authors: G. Mccutchan, J. Hiscock, P. Murchie, K. Hood, R. Neal, S. Thomas, A.M. Thomas, G. Newton, K. Brain
Journal: Journal of Thoracic Oncology (2018)
Sensitive and rapid detection of<i>TERT</i>promoter and<i>IDH</i>mutations in diffuse gliomas
Authors: Bill H Diplas, Heng Liu, Rui Yang, Landon J Hansen, Alexis L Zachem, Fangping Zhao, Darell D Bigner, Roger E McLendon, Yuchen Jiao, Yiping He, Matthew S Waitkus, Hai Yan
Journal: Neuro-Oncology (2018)

Mutations in telomerase reverse transcriptase promoter (TERTp) and isocitrate dehydrogenase 1 and 2 (IDH) offer objective markers to assist in classifying diffuse gliomas into genetic subgroups. However, traditional mutation detection techniques lack sensitivity or have long turnaround times or high costs. We developed GliomaDx, an allele-specific, locked nucleic acid-based quantitative PCR assay to overcome these limitations and sensitively detect TERTp and IDH mutations.
Cam morphology in young male football players mostly develops before proximal femoral growth plate closure: a prospective study with 5-yearfollow-up
Authors: Pim van Klij, Marinus P Heijboer, Abida Z Ginai, Jan A N Verhaar, Jan H Waarsing, Rintje Agricola
Journal: British Journal of Sports Medicine (2018)

Cam morphology is not completely understood. The aim of this study was threefold: (1) to investigate if cam morphology development is associated with growth plate status; (2) to examine whether cam morphology continues to develop after growth plate closure; and (3) to qualitatively describe cam morphology development over 5-year follow-up.Academy male football players (n=49) participated in this prospective 5-year follow-up study (baseline 12-19 years old). Anteroposterior and frog-leg lateral views were obtained at baseline (142 hips), 2.5-year (126 hips) and 5-year follow-up (98 hips). Cam morphology on these time points was defined as: (A) visual scores of the anterior head-neck junction, classified as: (1) normal, (2) flattening, and (3) prominence; and (B) alpha angle ≥60°. Proximal femoral growth plates were classified as open or closed. Cam morphology development was defined as every increase in visual score and/or increase in alpha angle from <60° to ≥60°, between two time points. This resulted in 224 measurements for cam morphology development analysis.Cam morphology development was significantly associated with open growth plates based on visual score (OR: 10.03, 95% CI 3.49 to 28.84, p<0.001) and alpha angle (OR: 2.85, 95% CI 1.18 to 6.88, p=0.020). With both definitions combined, cam developed in 104 of 142 hips during follow-up. Of these 104 hips, cam developed in 86 hips (82.7%) with open growth plate and in 18 hips (17.3%) with a closed growth plate. Cam morphology developed from 12 to 13 years of age until growth plate closure around 18 years.Cam morphology of the hip is more likely to develop with an open growth plate.
GW29-e1774 Serum Level of anti-ANT antibody and anti-β1R antibody in patients of dilated cardiomyopathy with different pathogeny and analysis of prognosis
Authors: Yu Hou, Baihui Zhang, Qingyan Zhang, Xiaozhen Sun, Shengnan Liu, Xiaochun Chen
Journal: Journal of the American College of Cardiology (2018)
Thromboembolic risk and survival with Khorana score in resected colorectal cancer patients: Subgroup analysis from the adjuvant TOSCA trial
Authors: S. Barni, G. Rosati, V. Zagonel, N. Pella, M. Banzi, M.G. Zampino, M. Di Bartolomeo, L. Rimassa, P. Marchetti, E. Maiello, F. Artioli, D. Ferrari, R. Labianca, P. Bidoli, A. Zaniboni, A. Sobrero, V. Iaffaioli, S. de Placido, L.G. Frassineti, F. Galli, F. Petrelli
Journal: Annals of Oncology (2018)
Endoscopic ultrasound-guided choledochoduodenostomy with electrocautery-enhanced lumen-apposing stents: a retrospective analysis
Authors: Jeremie Jacques, Jocelyn Privat, Fabien Pinard, Fabien Fumex, Jean-Christophe Valats, Azzedine Chaoui, Franck Cholet, Bruno Godard, Philippe Grandval, Romain Legros, Sebastien Kerever, Bertrand Napoleon
Journal: Endoscopy (2018)

Endoscopic ultrasound-guided biliary drainage is an alternative to percutaneous biliary drainage in cases of malignant biliary obstruction and failure of classic endoscopic drainage by endoscopic retrograde cholangiopancreatography (ERCP). Recently, a new electrocautery-enhanced lumen-apposing metal stent (ECE-LAMS) that allows for endoscopic anastomosis (apposition stent) has become available for use in EUS-choledochoduodenostomy (EUS-CDS) and facilitates the procedure.This was a retrospective study of all EUS-CDS procedures performed in France between April 2016 and August 2017. The primary end point was the technical and clinical success rates of EUS-CDS using an ECE-LAMS.52 consecutive patients were included in the study. The etiology of distal bile duct obstruction was distal pancreatic adenocarcinoma in 43 patients (82.7 %). The technical success rate was 88.5 % (46 /52 patients), and the clinical success rate was 100 % (46/46 patients). The mean duration of the procedure was 10.2 minutes (range 1 - 90). Two patients (3.8 %) presented with short-term complications after EUS-CDS and before discharge from hospital. In univariate analyses, a small diameter of the common bile duct and not following the recommended procedure technique were significant risk factors for technical failure. Over a mean follow-up of 157 days, the median survival time without biliary complications was 135 days.EUS-CDS with an ECE-LAMS is efficacious and safe in distal malignant obstruction of the common bile duct and could be proposed as the first option in cases of ERCP failure.
Letter by Madias Regarding Article, “NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?)”
Authors: John E. Madias
Journal: Circulation (2018)
Telemetric Intraocular Pressure Monitoring after Boston Keratoprosthesis Surgery
Authors: Philip Enders, Jonathan Hall, Marco Bornhauser, Kaweh Mansouri, Lebriz Altay, Stefan Schrader, Thomas S. Dietlein, Bjoern O. Bachmann, Thomas Neuhann, Claus Cursiefen
Journal: Ophthalmology (2018)
High-Molecular-Weight von Willebrand Factor Multimer Ratio
Authors: Joerg Kellermair, Helmut W. Ott, Helmut Baumgartner, Daniel Kiblboeck, Hermann Blessberger, Juergen Kammler, Christian Reiter, Thomas Lambert, Michael Grund, Clemens Steinwender
Journal: Journal of the American College of Cardiology (2018)
Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing
Authors: Thomas P. Slavin, Kimberly C. Banks, Darya Chudova, Geoffrey R. Oxnard, Justin I. Odegaard, Rebecca J. Nagy, Kar Wing Kevin Tsang, Susan L. Neuhausen, Stacy W. Gray, Massimo Cristofanilli, Angel A. Rodriguez, Aditya Bardia, Brian Leyland-Jones, Mike F. Janicek, Michael Lilly, Guru Sonpavde, Christine E. Lee, Richard B. Lanman, Funda Meric-Bernstam, Razelle Kurzrock, Jeffrey N. Weitzel
Journal: Journal of Clinical Oncology (2018)

Purpose To determine the potential for detection of incidental germline cancer predisposition mutations through cell-free DNA (cfDNA) analyses in patients who underwent solid tumor somatic mutation evaluation. Patients and Methods Data were evaluated from 10,888 unselected patients with advanced (stage III/IV) cancer who underwent Guardant360 testing between November 2015 and December 2016. The main outcome was prevalence of putative germline mutations identified among 16 actionable hereditary cancer predisposition genes. Results More than 50 cancer types were studied, including lung (41%), breast (19%), colorectal (8%), prostate (6%), pancreatic (3%), and ovarian (2%). Average patient age was 63.5 years (range, 18 to 95 years); 43% were male. One hundred and fifty-six individuals (1.4%) had suspected hereditary cancer mutations in 11 genes. Putative germline mutations were more frequent in individuals younger than 50 years versus those 50 years and older (3.0% v 1.2%, respectively; P &lt; .001). Highest yields of putative germline findings were in patients with ovarian (8.13%), prostate (3.46%), pancreatic (3.34%), and breast (2.2%) cancer. Putative germline mutation identification was consistent among 12 individuals with multiple samples. Patients with circulating tumor DNA copy number variation and/or reversion mutations suggestive of functional loss of the wild-type allele in the tumor DNA also are described. Conclusion Detection of putative germline mutations from cfDNA is feasible across multiple genes and cancer types without prior mutation knowledge. Many mutations were found in cancers without clear guidelines for hereditary cancer genetic counseling/testing. Given the clinical significance of identifying hereditary cancer predisposition for patients and their families as well as targetable germline alterations such as in BRCA1 or BRCA2, research on the best way to validate and return potential germline results from cfDNA analysis to clinicians and patients is needed.
A Single-Dose Live-Attenuated Zika Virus Vaccine with Controlled Infection Rounds that Protects against Vertical Transmission
Authors: Xuping Xie, Dieudonné B. Kum, Hongjie Xia, Huanle Luo, Chao Shan, Jing Zou, Antonio E. Muruato, Daniele B.A. Medeiros, Bruno T.D. Nunes, Kai Dallmeier, Shannan L. Rossi, Scott C. Weaver, Johan Neyts, Tian Wang, Pedro F.C. Vasconcelos, Pei-Yong Shi
Journal: Cell Host & Microbe (2018)
The role of primary tumour location in the recurrence rate of metachronous metastasis of colon cancer
Authors: M. Rimini, C. Bardasi, F. Gelsomino, K. Andrikou, C. Santini, G. Orsi, M. Salati, M.L. Riggi, S. Pipitone, S. Cascinu, A. Spallanzani
Journal: Annals of Oncology (2018)